Ajanta Pharma is currently trading at Rs. 1343.00, up by 6.80 points or 0.51% from its previous closing of Rs. 1336.20 on the BSE.
The scrip opened at Rs. 1360.00 and has touched a high and low of Rs. 1360.00 and Rs. 1322.75 respectively. So far 26598 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1922.00 on 08-Dec-2016 and a 52 week low of Rs. 1106.00 on 22-Aug-2017.
Last one week high and low of the scrip stood at Rs. 1360.00 and Rs. 1208.00 respectively. The current market cap of the company is Rs. 11854.23 crore.
The promoters holding in the company stood at 70.70%, while Institutions and Non-Institutions held 17.63% and 11.67% respectively.
Ajanta Pharma has launched Clonidine Hydrochloride Extended Release Tablets in the US Market through its wholly owned subsidiary Ajanta Pharma USA. It is a bioequivalent generic version of Kapvay Tablets and company has launched the product in 0.1mg dosage.
Clonidine Hydrochloride Extended Release Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 39 Abbreviated New Drug Applications (ANDAs) of which it has 22 final ANDA approvals, 2 tentative approvals, and 15 ANDAs under review with USFDA. Till date, it has launched 16 products in the US market.
Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: